[go: up one dir, main page]

MX2010003217A - Celulas angiogenicas de perfundido de placenta humana. - Google Patents

Celulas angiogenicas de perfundido de placenta humana.

Info

Publication number
MX2010003217A
MX2010003217A MX2010003217A MX2010003217A MX2010003217A MX 2010003217 A MX2010003217 A MX 2010003217A MX 2010003217 A MX2010003217 A MX 2010003217A MX 2010003217 A MX2010003217 A MX 2010003217A MX 2010003217 A MX2010003217 A MX 2010003217A
Authority
MX
Mexico
Prior art keywords
placental
placental perfusate
cells
perfusate
human placental
Prior art date
Application number
MX2010003217A
Other languages
English (en)
Inventor
Mohammad A Heidaran
Xiaokui Zhang
Vanessa A Voskinarian-Berse
Lin Kang
Henry Rendon Barrigan
Original Assignee
Celgene Cellular Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Cellular Therapeutics filed Critical Celgene Cellular Therapeutics
Publication of MX2010003217A publication Critical patent/MX2010003217A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporciona la producción de células vasculogénicas y angiogénicas de perfundido de placenta. También se proporcionan los métodos de tratamiento a un individuo que tenga una insuficiencia, enfermedad, trastorno o condición cardiaca o vascular, que consisten en administrar al individuo perfundido de placenta, células de perfundido de placenta o combinaciones de perfundido de placenta o células de perfundido con células madre hematopoyéticas placentarias o no placentarias o células madre placentarias adherentes.
MX2010003217A 2007-09-26 2008-09-26 Celulas angiogenicas de perfundido de placenta humana. MX2010003217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99567907P 2007-09-26 2007-09-26
PCT/US2008/011167 WO2009042201A1 (en) 2007-09-26 2008-09-26 Angiogenic cells from human placental perfusate

Publications (1)

Publication Number Publication Date
MX2010003217A true MX2010003217A (es) 2010-07-30

Family

ID=40043062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003217A MX2010003217A (es) 2007-09-26 2008-09-26 Celulas angiogenicas de perfundido de placenta humana.

Country Status (12)

Country Link
US (1) US20090104164A1 (es)
EP (1) EP2205719A1 (es)
JP (6) JP5703493B2 (es)
KR (9) KR20200136051A (es)
CN (1) CN101978045A (es)
AU (1) AU2008305516A1 (es)
BR (1) BRPI0818191A8 (es)
CA (1) CA2700613C (es)
IL (4) IL204762A0 (es)
MX (1) MX2010003217A (es)
RU (1) RU2010116271A (es)
WO (1) WO2009042201A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435594C1 (ru) * 2010-10-04 2011-12-10 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ лечения плацентарной недостаточности во ii-iii триместрах беременности

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2522890T3 (es) * 2000-12-06 2014-11-19 Anthrogenesis Corporation Método para recolectar células troncales placentarias
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP3246396B1 (en) 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2505534A1 (en) * 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
JP2007531116A (ja) * 2004-03-26 2007-11-01 セルジーン・コーポレーション 幹細胞バンクを提供するためのシステム及び方法
ES2452595T3 (es) * 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
NZ567334A (en) * 2005-10-13 2012-08-31 Anthrogenesis Corp Production of oligodendrocytes from placenta-derived stem cells
EP1974013A2 (en) * 2005-12-29 2008-10-01 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
ES2549111T3 (es) 2005-12-29 2015-10-23 Anthrogenesis Corporation Poblaciones de células madre placentarias
EP2412801A1 (en) * 2005-12-29 2012-02-01 Anthrogenesis Corporation Co-Culture of placental stem cells and stem cells from a second source
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CA2667359C (en) 2006-10-23 2014-07-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2008100497A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
DK2120977T3 (da) 2007-02-12 2013-08-12 Anthrogenesis Corp Behandling af inflammatoriske sygdomme under anvendelse af placenta-stamceller
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US20090104164A1 (en) * 2007-09-26 2009-04-23 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
CN101878034B (zh) 2007-09-28 2013-11-20 细胞基因细胞疗法公司 使用人胎盘灌洗液和人来自胎盘的中间体自然杀伤细胞的肿瘤抑制
KR20200143506A (ko) * 2008-08-20 2020-12-23 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
ES2612469T3 (es) 2008-08-20 2017-05-17 Anthrogenesis Corporation Composición celular mejorada y métodos de elaboración de la misma
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
JP5869342B2 (ja) 2008-11-19 2016-02-24 アンスロジェネシス コーポレーション 羊膜由来接着細胞
MX353489B (es) * 2009-07-02 2018-01-16 Anthrogenesis Corp Metodo para producir eritrocitos sin celulas alimentadoras.
US9163212B2 (en) 2010-01-25 2015-10-20 Warsaw Orthopedic, Inc. Osteogenic cell delivery matrix
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
US20110212065A1 (en) 2010-02-18 2011-09-01 Timothy Jansen Methods of manufacture of therapeutic products comprising vitalized placental dispersions
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
JP5996533B2 (ja) 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP2016506968A (ja) 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション 胎盤由来のナチュラルキラー細胞
JP6571537B2 (ja) * 2013-03-13 2019-09-04 ザ ユニバーシティー オブ クイーンズランド 療法および予防のための細胞を単離する方法
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
HK1221402A1 (zh) 2013-04-02 2017-06-02 University Of Florida Research Foundation, Inc. 用於诱导并调节血管生成的组合物和方法以及用於鉴别血管生成调节剂的方法和实验
EP3068432A4 (en) 2013-11-15 2017-04-19 Anthrogenesis Corporation Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
CN103756965B (zh) * 2014-01-27 2016-04-06 山东省齐鲁干细胞工程有限公司 一种从胎盘中灌洗造血干细胞的方法
CN104152405B (zh) * 2014-08-15 2016-06-29 博雅干细胞科技有限公司 从胎盘中分离提取造血干细胞的方法
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US20180216065A1 (en) * 2015-07-20 2018-08-02 The Catholic University Of Korea Industry-Academic Cooperation Foundation Method for Inducing Differentiation of Myeloid-Derived Suppressor Cells from Cord - Blood CD34 Positive Cells and Proliferating Same, and use of Myeloid-Derived
KR20170020273A (ko) * 2015-08-12 2017-02-22 (주)차바이오텍 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도
AU2017373862A1 (en) * 2016-12-05 2019-06-27 Celularity Inc. Treatment of lymphedema and related conditions using placental adherent cells
CN107058224B (zh) * 2017-02-10 2020-08-21 广东唯泰生物科技有限公司 一种以胎盘为来源的造血干细胞提取及冻存方法
WO2020113182A1 (en) 2018-11-30 2020-06-04 Celularity, Inc. Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
CN109652372A (zh) * 2019-01-09 2019-04-19 陕西九州细胞基因工程有限公司 一种人胎盘组织源造血干细胞的快速分离、制备方法
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
WO2020252464A1 (en) 2019-06-14 2020-12-17 Celularity Inc. Populations of natural killer cells for treating cancers
US20220273716A1 (en) 2019-07-25 2022-09-01 Celularity Inc. Populations of natural killer cells comprising a cd38 chimeric antigen receptor
WO2021022229A1 (en) 2019-07-31 2021-02-04 Celularity Inc. Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en) 2019-12-05 2021-06-10 Celularity Inc. Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
WO2021155312A1 (en) 2020-01-29 2021-08-05 Celularity Inc. Placental derived natural killer cells for treatment of coronavirus infections
WO2023278628A1 (en) 2021-06-29 2023-01-05 Celularity Inc. Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml
US20250276063A1 (en) 2021-07-29 2025-09-04 Celularity Inc. Placenta-dervied nk cells as a senol ytic for therapeutic and other uses
AU2023206330A1 (en) 2022-01-11 2024-08-22 Celularity Inc. Cleavage resistant cd16 constructs and uses thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862002A (en) * 1962-05-08 1975-01-21 Sanfar Lab Inc Production of physiologically active placental substances
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
ES2185649T3 (es) * 1993-03-31 2003-05-01 Wellstat Therapeutics Corp Inhibidores de la proliferacion de las celulas germinales y sus utilizaciones.
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
JPH10505250A (ja) * 1994-06-06 1998-05-26 ケース ウエスターン リザーブ ユニバーシティ 組織再生のためのバイオマトリックス
US6174333B1 (en) * 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US6103522A (en) * 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en) * 1995-04-21 1998-03-31 The Regent Of The University Of Michigan Hematopoietic cells: compositions and methods
US5925567A (en) * 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
US5858782A (en) * 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
WO1997019172A1 (en) * 1995-11-17 1997-05-29 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
EP2105138A3 (en) * 1996-04-19 2013-06-05 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
US5919176A (en) * 1996-05-14 1999-07-06 Children's Hospital Medical Center Of Northern California Apparatus and method for collecting blood from an umbilical cord
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5916202A (en) * 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5879318A (en) * 1997-08-18 1999-03-09 Npbi International B.V. Method of and closed system for collecting and processing umbilical cord blood
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
ES2237089T3 (es) * 1998-03-13 2005-07-16 Osiris Therapeutics, Inc. Usos para celulas madre mesenquimatosas humanas no autologas.
EP1108011A2 (en) * 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
JP3089299B2 (ja) * 1998-12-14 2000-09-18 京都大学長 生体内に毛細血管が豊富な組織を作成するのに用いる新生血管床形成用用具
HK1046154B (zh) * 1999-02-04 2009-12-31 Pluristem Ltd. 维持和扩增造血干细胞和/或祖细胞的方法和仪器
FR2792202B1 (fr) * 1999-04-19 2003-06-13 Pharmascience Lab Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
ES2522890T3 (es) * 2000-12-06 2014-11-19 Anthrogenesis Corporation Método para recolectar células troncales placentarias
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
IL157350A0 (en) * 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
CA2396536A1 (en) * 2001-08-10 2003-02-10 Saiko Uchida Human stem cells originated from human amniotic mesenchymal cell layer
WO2003061591A2 (en) * 2002-01-22 2003-07-31 Advanced Cell Technology, Inc. Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
NZ534643A (en) * 2002-02-13 2010-06-25 Anthrogenesis Corp Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
GB0205867D0 (en) * 2002-03-13 2002-04-24 Univ Nottingham Polymer composite loaded with functioning matter
US20030187515A1 (en) * 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1525308A4 (en) * 2002-05-30 2006-11-02 Celgene Corp METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASIC SYNDROMES
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
JP4480128B2 (ja) * 2002-11-20 2010-06-16 独立行政法人科学技術振興機構 マトリックスメタロプロテアーゼ−９の産生を阻害するための薬剤
JP2006517975A (ja) * 2003-02-13 2006-08-03 アンスロジェネシス コーポレーション 疾患、障害または症状を患っている個体を治療するための臍帯血の使用
WO2005001079A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US7569385B2 (en) * 2003-08-14 2009-08-04 The Regents Of The University Of California Multipotent amniotic fetal stem cells
AR046123A1 (es) * 2003-10-17 2005-11-23 Crc For Innovative Dairy Produ Aislamiento de celulas simil-celulas madre, uso de las mismas
JP2007536909A (ja) * 2003-12-29 2007-12-20 センテリオン 冠動脈または末梢性虚血の治療
KR20070037444A (ko) * 2004-06-15 2007-04-04 백스터 인터내셔널 인코포레이티드 고체 미립자성 치료제의 생체외 적용방법
US7147626B2 (en) * 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US7909806B2 (en) * 2004-09-23 2011-03-22 Anthrogenesis Corporation Cord blood and placenta collection kit
US8017395B2 (en) * 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US9056093B2 (en) * 2005-01-07 2015-06-16 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2006091766A2 (en) * 2005-02-24 2006-08-31 Jau-Nan Lee Human trophoblast stem cells and use thereof
US20060222634A1 (en) * 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
AU2006235211B2 (en) * 2005-04-12 2010-10-14 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2006135843A2 (en) * 2005-06-10 2006-12-21 Celgene Corporation Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
BRPI0612121A2 (pt) * 2005-06-30 2016-09-06 Anthrogenesis Corp método de reparo de uma membrana timpânica que tenha uma deformidade, e, biotecido de colágeno
WO2007009061A2 (en) * 2005-07-13 2007-01-18 Anthrogenesis Corporation Ocular plug formed from placenta derived collagen biofabric
US7928280B2 (en) * 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
ES2452595T3 (es) * 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
AU2006330409B2 (en) * 2005-12-28 2012-07-19 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
ES2549111T3 (es) * 2005-12-29 2015-10-23 Anthrogenesis Corporation Poblaciones de células madre placentarias
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
WO2007146105A2 (en) * 2006-06-05 2007-12-21 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
ZA200810412B (en) * 2006-06-09 2010-03-31 Anthrogenesis Corp Placental niche and use thereof to culture stem cells
US20090081171A1 (en) * 2006-08-11 2009-03-26 Yu-Show Fu Cell system for alleviating syndromes of Parkinson's disease in a mammal
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US20080050347A1 (en) * 2006-08-23 2008-02-28 Ichim Thomas E Stem cell therapy for cardiac valvular dysfunction
CA2667359C (en) * 2006-10-23 2014-07-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2008100497A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20090016999A1 (en) * 2007-07-13 2009-01-15 Michael Cohen Embryonic cell compositions for wound treatment
MX2008005751A (es) * 2007-09-13 2009-04-16 Clifford L Librach Metodo de aislamiento y uso de celulas derivadas del tejido del cordon umbilical del primer trimestre.
RU2010109698A (ru) * 2007-09-19 2011-09-27 Плуристем Лтд. (Il) Адгезивные клетки жировой ткани или плаценты и их использование в лечебных целях
US20090104164A1 (en) * 2007-09-26 2009-04-23 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
ES2612469T3 (es) * 2008-08-20 2017-05-17 Anthrogenesis Corporation Composición celular mejorada y métodos de elaboración de la misma
KR20200143506A (ko) * 2008-08-20 2020-12-23 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
CA2734446C (en) * 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
CN201299504Y (zh) * 2008-11-11 2009-09-02 薛华 一种方便搭挂的毛巾
MX353489B (es) * 2009-07-02 2018-01-16 Anthrogenesis Corp Metodo para producir eritrocitos sin celulas alimentadoras.
TWI395125B (zh) * 2009-07-14 2013-05-01 Sonix Technology Co Ltd 電容式觸控感應電路

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435594C1 (ru) * 2010-10-04 2011-12-10 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ лечения плацентарной недостаточности во ii-iii триместрах беременности

Also Published As

Publication number Publication date
JP2022166249A (ja) 2022-11-01
JP5985569B2 (ja) 2016-09-06
WO2009042201A1 (en) 2009-04-02
KR20210118946A (ko) 2021-10-01
CA2700613A1 (en) 2009-04-02
JP5703493B2 (ja) 2015-04-22
CN101978045A (zh) 2011-02-16
BRPI0818191A2 (pt) 2017-06-13
KR20220122774A (ko) 2022-09-02
KR20160092062A (ko) 2016-08-03
IL204762A0 (en) 2010-12-30
IL260292A (en) 2018-07-31
KR20100091160A (ko) 2010-08-18
KR20200043517A (ko) 2020-04-27
BRPI0818191A8 (pt) 2017-10-03
US20090104164A1 (en) 2009-04-23
IL242645B (en) 2018-07-31
AU2008305516A1 (en) 2009-04-02
RU2010116271A (ru) 2011-11-10
KR20150090276A (ko) 2015-08-05
JP2018172425A (ja) 2018-11-08
JP2017002071A (ja) 2017-01-05
JP2015042648A (ja) 2015-03-05
CA2700613C (en) 2022-09-20
JP2010540530A (ja) 2010-12-24
JP2020189872A (ja) 2020-11-26
EP2205719A1 (en) 2010-07-14
KR20190050867A (ko) 2019-05-13
KR20200136051A (ko) 2020-12-04
KR20180059583A (ko) 2018-06-04
KR101644659B1 (ko) 2016-08-01
IL242644B (en) 2018-07-31
KR101645311B1 (ko) 2016-08-03

Similar Documents

Publication Publication Date Title
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
MX2022014414A (es) Compuestos de pirimidinodiona contra estados cardiacos.
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
WO2006050330A3 (en) Platelets from stem cells
WO2008017025A3 (en) Combination therapy
WO2010007031A3 (en) Methods for improving cardiac differentiation of human embryonic stem cells
AU2012388759A8 (en) Methods and compositions for hypotensive resuscitation
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2006073890A3 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
MX2014005895A (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
MX2010006443A (es) TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.
WO2015069979A3 (en) Sulfated and unsulfated flavonoid oligomers as cancer therapeutics
WO2012061811A3 (en) Anti- connective tissue growth factor agent for use in the treatment of lung remodeling disease
HK1140515A (en) Angiogenic cells from human placental perfusate
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
WO2014144731A3 (en) Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
UA65525U (ru) Способ лечения больных ишемической болезнью сердца
UA68459U (ru) Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
UA48652U (ru) Способ оценки эффективности лечения больных ишемической болезнью сердца со стенокардией и артериальной гипертензией спираприлом
UA68460U (ru) Способ оценки эффективности лечения s-атенололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
Reynolds Cardiac resynchronization for heart failure: Its time has come

Legal Events

Date Code Title Description
FA Abandonment or withdrawal